Journals / Dicle Tıp Dergisi / 2010 / Cilt: 37 - Sayı: 2

Effects of valsartan and nebivolol on blood pressure, QT dispersion and left ventricular hypertrophy in hypertensive patients

Hipertansif hastalarda valsartan ve nebivololun, kan basıncı, QT dağılımı ve sol ventrikül hipertrofisi üzerine etkileri

Pages
81–88
Publication Date
2010-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The range of mean systolic blood pressure (SBP) varied from 152±17 (baseline) to 132±17 mmHg (follow-up) in the Valsartan group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to analyze the an­tihypertensive effect of Valsartan and Nebivolol and their effects on QT dispersion and left ventricular hypertrophy (LVH) in the treatment of naive hypertensive patients.
📊
Key Findings & Data:Methods: A prospective study with a six-month follow-up was conducted on hypertensive patients with LVH and mild/ moderate essential hypertension.
💡
Conclusion & Impact:Results: The range of mean systolic blood pressure (SBP) varied from 152±17 (baseline) to 132±17 mmHg (follow-up) in the Valsartan group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hipertansiyon · elektrokardiyografi · sol ventrikül hipertrofisi

Abstract

Objectives: The aim of this study was to analyze the an­tihypertensive effect of Valsartan and Nebivolol and their effects on QT dispersion and left ventricular hypertrophy (LVH) in the treatment of naive hypertensive patients. Methods: A prospective study with a six-month follow-up was conducted on hypertensive patients with LVH and mild/ moderate essential hypertension. The patients were randomly assigned to Valsartan (80 to 160 mg/day) or Nebivolol (5 to 10 mg/day) groups. The study group con­sisted of 108 patients, 55 in the Valsartan group and 53 in the Nebivolol group. Results: The range of mean systolic blood pressure (SBP) varied from 152±17 (baseline) to 132±17 mmHg (follow-up) in the Valsartan group (p

Özet

Amaç: Bu çalışmanın amacı valsartan ve nebivololun an­tihipertansif etkilerini ve bu ilaçların hipertansif hastaların tedavisinde QT dağılımı ve sol ventrikül hipertrofisi üzeri­ne etkilerini analiz etmektir. Yöntemler: Sol ventrikül hipertrofisi (SVH) bulunan ha­fif/orta hipertansiyonlu hastalarda 6 ay süreli takip içe­ren prospektif bir çalışma düzenlendi. Hastalar rastgele olarak Valsartan (80-160 mg/gün) veya Nebivolol (5-10 mg/gün) gruplarına alındı. Çalışma grubu 55\'i Valsartan grubu, 53\'ü Nebivolol grubunda olmak üzere toplam 108 hastadan oluşturuldu. Bulgular: Valsartan grubunda ortalama sistolik kan ba­sıncı (SKB) 152±17 mmHg (bazal)\'den 132±17 mmHg (takip)\'e değişti (p

🔖

Cite This Article

LăţEA, L., NEGREA, Ş. L., BOLBOACă, S. D. (2010). Effects of valsartan and nebivolol on blood pressure, QT dispersion and left ventricular hypertrophy in hypertensive patients. Dicle Tıp Dergisi, Cilt: 37 - Sayı: 2, 81–88. https://ajindex.com/articles/485474

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13:82-8.
  2. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation 1987;75:126-33.
  3. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long QT syndrome. N Engl J Med 2003;348:1866- 74. Bazett HC. An analysis of the time-relations of electrocardio- grams. Heart 1920;7:353-70.
  4. Oikarinen L, Nieminen MS, Viitasalo M, et al. LIFE Study Investigators. QRS duration and QT interval predict mor- tality in hypertensive patients with left ventricular hyper- trophy. Hypertension 2004;43:1029-34.
  5. Rasmussen KG, Hooten WM, Dodd ML, Ryan DA.QTc dis- persion on the baseline ECG predicts arrhythmias during electroconvulsive therapy. Acta Cardiol 2007;62:345-7.
  6. Yildirir A, Batur MK, Oto A. Hypertension and arrhythmia: blood pressure control and beyond. Europace 2002;4:175- 82. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essen- tial hypertension. Am J Med 2003;115 41-6.
  7. Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: Focus on left ven- tricular hypertrophy regression and atrial fibrillation pre- vention. Vasc Health Risk Manag 2008;4: 67-73.
  8. Lim PO, Nys M, Naas AA, et al. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999;33:713-8.
  9. Sampson UK, Pfeffer MA, McMurray JJV, et al. Predic- tors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. Eur Heart J 2007;28: 685-91.
  10. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res 1998;38:419-31.
  11. Sule SS, Frishman W. Nebivolol: new therapy update. Car- diol Rev 2006;14:259-64.
  12. Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-genera- tion ß-adrenergic blocker. Ann Pharmacother 2006;40:1353- 60. Pessina AC. Metabolic effects and safety profile of nebiv- olol. J Cardiovasc Pharmacol 2001;38:S33-S35. Toda N. Vasodilating ß-adrenoceptor blockers as cardiovas- cular therapeutics. Pharmacol Ther 2003;100:215-34.
  13. Ambrosioni E, Borghi C. Tolerability of nebivolol in head- tohead clinical trials versus other cardioselective β-blockers in the treatment of hypertension: a meta-analysis. High Blood Press Cardiovasc Prev 2005;12:27-35. European Society of Hypertension - European Society if Cardiology Guidelines Commit